CD160 and systemic lupus erythematosus: SLE patients with high disease activity (SLEDAI < 6 vs. SLEDAI ≥ 6) have expanded cell numbers of CD3 + CD160 + (14.32 ± 1.012%, (N = 64) vs 22.22 ± 3.09%, (N = 23), p = 0.0022).